DCP Cancer Symptom Science Updates: NOFOs and More

National Cancer Institute sent this bulletin at 11/20/2024 10:30 AM EST

Having trouble viewing this email? View it as a Web page.

Division of Cancer Prevention Symptom Science Updates

Notice of Funding Opportunity

Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

A patient lying on a hospital bed, looking out of the window.

The purpose of this Notice of Funding Opportunity (NOFO) is to promote research studies designed to address adverse sequelae of cancer therapies that persist and become chronic co-morbidities or develop as delayed posttreatment effects.

PAR-25-145

Expires: January 8, 2028

Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3 - Clinical Trial Optional)

A medical professional displaying an application on a mobile phone to a patient.

The purpose of this NOFO is to support rigorous development and validation of Digital Health Technology (DHT) derived biomarkers or clinical outcome assessments (COAs) for remote monitoring to fill a defined unmet clinical endpoint for interventional clinical trials.

Includes development and validation of digital biomarkers to monitor cancer treatment related symptoms, sequelae, and/or outcomes (e.g., pain, cognitive impairment, adverse events, late effects toxicity).

PAR-25-170

Expires: June 23, 2026

Upcoming Events

NCI Cancer Integrative Medicine Grantee Conference

A collage of complementary medicine images including tai chi, green tea, acupuncture, and massage.

The NCI Cancer Integrative Medicine Grantee Conference will be held on December 10-11, 2024. This event is open to the public and registration is required.

This free virtual conference will provide opportunities for learning about grantsmanship, tools, and resources from the NCI and the National Institutes of Health (NIH), and for NCI program staff to hear about grantee needs and challenges. The conference will also highlight NCI/NIH funded cancer-related complementary and integrative medicine research and identify gaps or needs for translational and clinical research, and technology to advance precision integrative oncology across the cancer continuum.